If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

The agency suggested that clinical trials in humans may be required for updated Covid shots, raising questions about whether ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

“Under Secretary Kennedy’s leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to ...

Pfizer Inc. and BioNTech SE failed to knock out any of Alnylam Pharmaceuticals Inc.’s patents in a case over the partners’ ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

An administration spokesman didn't respond to specific questions about Pfizer and Moderna but suggested all COVID-19 vaccines could face stricter requirements. “It’s now been years since COVID ...

01. Confusion over the Food and Drug Administration’s delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend when the agency’s commissioner, Marty Makary ...